Metformin attenuates hypoxia‑induced resistance to cisplatin in the HepG2 cell line

Abstract

Hepatoblastoma is the most commonly occurring liver tumor in children. Preoperative chemotherapy and surgery have improved treatment outcomes; however, further improvements are required in the treatment of advanced cases. Recently, the efficacy of transarterial chemoembolization (TACE) has garnered attention. TACE increases the local concentration of drugs by transcatheterically administering antitumor agents, and induces necrosis in the tumor by embolizing the feeding artery. However, studies have revealed that tumors exhibit resistance to anticancer drugs in hypoxic environments. Metformin is a drug used to treat type 2 diabetes; however, recent reports have indicated that it may also exhibit antitumor effects in various cancer cell lines. These effects are hypothesized to be mediated by the activation of adenosine monophosphate-activated protein kinase and reduction of mammalian target of rapamycin signaling, but these effects occur at high concentrations that are not suitable for use in a clinical setting. The potential efficacy of metformin at increased physiological concentrations has not been evaluated. The present study investigated the therapeutic effect of low concentrations of metformin in combination with cisplatin on liver cancer HepG2 cells in hypoxic conditions. HepG2 cells were treated with cisplatin alone, metformin alone, or a combination of these two drugs and cultured in normoxia or hypoxia. Treatment with either 5 µM cisplatin or 1 mM metformin alone did not significantly affect cell proliferation or apoptosis in hypoxic conditions. However, when 5 µM cisplatin was combined with 1 mM metformin, a significant inhibition of cell proliferation and induction of apoptosis was observed in hypoxic HepG2 cells. In conclusion, a low concentration of metformin attenuates hypoxia-induced resistance to cisplatin in HepG2 cells. Selective delivery of an effective dose of metformin to a hepatoblastoma tumor may be achievable and clinically useful with TACE.

<p>Melatonin Regulates Cisplatin Resistance and Glucose Metabolism Through Hippo Signaling in Hepatocellular Carcinoma Cells</p>

“…The restoration of YAP partially undermined the inhibitive effect of MEL on HCC cells, suggesting MEL involved in Hippo signaling. Accumulating studies also implied that MEL enhances cisplatin anti-cancer effect in many cancer cells by stimulating mitochondrial ROS generation, 41 this aspect requires further investigation.…”

The therapeutic potential of metformin in gastric cancer

“…More studies are needed to confirm if, in the GC context, the association of metformin with conventional chemotherapies represents an interesting therapeutic perspective, as it is the case in hepatoblastoma for example, where metformin attenuated hypoxia-induced resistance to cisplatin in the human liver cancer cell line HepG2 [64]. This study clearly demonstrated that addition of metformin is better than conventional chemotherapy alone.…”

Hypoxia and its therapeutic possibilities in paediatric cancers

“…Metformin successfully restored chemosensitivity to cisplatin in hepatoblastoma cells under hypoxia. 86 Conversely, the inhibitory effects of metformin on tumour growth were reduced by hypoxia in childhood sarcoma xenografts. 87 The disparity in results may be due to the inherent differences between hepatomas and sarcomas and/or the variabilities in experimental details, including drug concentrations and methods used to induce hypoxia.…”